

# Appendix 1. Detailed Search Strategy

This appendix suggests the detailed search strategy. With each database and additional record, we specified relevant URL link.

**Supplement Table 1. Categories and identification numbers of databases and records**

Category	Name	No.	URL
electronic database	Pubmed	A1	<a href="http://www.ncbi.nlm.nih.gov/pubmed/">http://www.ncbi.nlm.nih.gov/pubmed/</a>
	Embase	A2	<a href="http://www.embase.com/#quickSearch/default">http://www.embase.com/#quickSearch/default</a>
	Cochrane Libray	A3	<a href="http://onlinelibrary.wiley.com/cochranelibrary/search/">http://onlinelibrary.wiley.com/cochranelibrary/search/</a>
	Scopus	A4	<a href="http://www.scopus.com/">http://www.scopus.com/</a>
additional search	ESMO	B1	<a href="https://www.webges.com/cslide/library/esmo/browse/search">https://www.webges.com/cslide/library/esmo/browse/search</a>
	ASCO	B2	<a href="http://meetinglibrary.asco.org/abstracts">http://meetinglibrary.asco.org/abstracts</a>
	UEGW	B3	<a href="https://www.ueg.eu/education/library/">https://www.ueg.eu/education/library/</a>
	DDW	B4	<a href="http://www.giejournal.org/issues">http://www.giejournal.org/issues</a>
	citation of relevant records	B5	manual search

We established a ‘two-track search strategy’; one track is an electronic database search (A1~A4) and the other is a manual search for additional records (B1~B5). Additional records were derived from major international conferences (B1~B4), and references from selected systematic review (B5).

**Abbreviation** - DB, database; AR, additional records; Onco, oncology; GI, gastrointestinal disease; ESMO, European Society of Medical Oncology; ASCO, American Society of Clinical Oncology; UEGW, United European Gastroenterology Week; DDW, Digestive Disease Week; SR, systematic review

## A1. PubMed

((pancreatic cancer) OR (pancreatic adenocarcinoma) OR (pancreatic neoplasm) OR (pancreatic tumor)) AND (resectable OR operable) AND (((neoadjuvant OR neo-adjuvant) OR (preop\* OR pre-op\*)) AND (chemotherapy OR chemoradiation OR chemoradiotherapy OR radiation OR radiotherapy))

→ 403 articles (+ human filter) → ( ) articles

((pancreatic cancer) OR (pancreatic adenocarcinoma) OR (pancreatic neoplasm) OR (pancreatic tumor)) AND (resectable OR operable) AND ((neoadjuvant OR neo-adjuvant) OR (preop\* OR pre-op\*)) → ( ) articles

*((("pancreatic neoplasms"[MeSH Terms] OR ("pancreatic"[All Fields] AND "neoplasms"[All Fields]) OR "pancreatic neoplasms"[All Fields] OR ("pancreatic"[All Fields] AND "cancer"[All Fields]) OR "pancreatic cancer"[All Fields]) OR (("pancreas"[MeSH Terms] OR "pancreas"[All Fields] OR "pancreatic"[All Fields]) AND ("adenocarcinoma"[MeSH Terms] OR "adenocarcinoma"[All Fields])) OR ("pancreatic neoplasms"[MeSH Terms] OR ("pancreatic"[All Fields] AND "neoplasms"[All Fields]) OR "pancreatic neoplasms"[All Fields] OR ("pancreatic"[All Fields] AND "neoplasm"[All Fields]) OR "pancreatic neoplasm"[All Fields]) OR ("pancreatic neoplasms"[MeSH Terms] OR ("pancreatic"[All Fields] AND "neoplasms"[All Fields]) OR "pancreatic neoplasms"[All Fields] OR ("pancreatic"[All Fields] AND "tumor"[All Fields]) OR "pancreatic tumor"[All Fields])) AND (resectable[All Fields] OR operable[All Fields]) AND (((("neoadjuvant therapy"[MeSH Terms] OR ("neoadjuvant"[All Fields] AND "therapy"[All Fields]) OR "neoadjuvant therapy"[All Fields] OR "neoadjuvant"[All Fields]) OR neo-adjuvant[All Fields]) OR (preoperative[All Fields] OR pre-operative[All Fields])) AND (("drug therapy"[Subheading] OR ("drug"[All Fields] AND "therapy"[All Fields]) OR "drug therapy"[All Fields] OR "chemotherapy"[All Fields] OR "drug therapy"[MeSH Terms] OR ("drug"[All Fields] AND "therapy"[All Fields]) OR "chemotherapy"[All Fields]) OR ("chemoradiotherapy"[MeSH Terms] OR "chemoradiotherapy"[All Fields] OR "chemoradiation"[All Fields]) OR ("chemoradiotherapy"[MeSH Terms] OR "chemoradiotherapy"[All Fields]) OR*

*("radiation"[MeSH Terms] OR "radiation"[All Fields] OR "electromagnetic radiation"[MeSH Terms] OR  
("electromagnetic"[All Fields] AND "radiation"[All Fields]) OR "electromagnetic radiation"[All Fields]) OR  
("radiotherapy"[Subheading] OR "radiotherapy"[All Fields] OR "radiotherapy"[MeSH Terms]))*

## **A2. Embase**

((pancreatic cancer) OR (pancreatic adenocarcinoma) OR (pancreatic neoplasm\*) OR  
(pancreatic tumor)) AND (resectable OR operable) AND (((neoadjuvant OR neo-adjuvant)  
OR (preop\* OR pre-op\*)) AND (chemotherapy OR chemoradiation OR chemoradiotherapy  
OR radiation OR radiotherapy))

→ ( ) articles (+ human filter) → ( ) articles

## **A3. Cochrane Library**

(pancreatic cancer OR pancreatic adenocarcinoma OR pancreatic neoplasm OR pancreatic  
tumor)

AND resectable → ( ) articles

## **A4. Scopus**

(pancreatic cancer OR pancreatic adenocarcinoma OR pancreatic neoplasm OR pancreatic  
neoplasms OR pancreatic tumor) AND (resectable OR operable) AND (neoadjuvant OR neo-  
adjuvant OR preoperative OR pre-operative) → ( ) articles

## **B1. ESMO (European Society of Medical Oncology)**

<https://www.webges.com/cslide/library/esmo/browse/search>

Because 2013 and 2011 of ESMO conference were held with ECCO and ESTRP conference, the applicable option is not listed in above URL. We found the individual link of each year's abstract table and suggest them as followings.

(2014) – ESMO 39<sup>th</sup> [http://annonc.oxfordjournals.org/content/25/suppl\\_4](http://annonc.oxfordjournals.org/content/25/suppl_4)

(2013) – ESMO 38<sup>th</sup> <http://2013.europeancancercongress.org/Scientific-Programme/Abstract-search>

(2012) – ESMO 37<sup>th</sup> [http://annonc.oxfordjournals.org/content/23/suppl\\_9](http://annonc.oxfordjournals.org/content/23/suppl_9)

(2011) – ESMO 36<sup>th</sup> <http://2011.europeancancercongress.org/Programme/Online-posters>

(2010) – ESMO 35<sup>th</sup> [http://annonc.oxfordjournals.org/content/21/suppl\\_8](http://annonc.oxfordjournals.org/content/21/suppl_8)

(2014) – ESMO GI 16<sup>th</sup> [http://annonc.oxfordjournals.org/content/25/suppl\\_2](http://annonc.oxfordjournals.org/content/25/suppl_2)

(2013) – ESMO GI 15<sup>th</sup> [http://annonc.oxfordjournals.org/content/24/suppl\\_4](http://annonc.oxfordjournals.org/content/24/suppl_4)

(2012) – ESMO GI 14<sup>th</sup> [http://annonc.oxfordjournals.org/content/23/suppl\\_4](http://annonc.oxfordjournals.org/content/23/suppl_4)

(2011) – ESMO GI 13<sup>th</sup> [http://annonc.oxfordjournals.org/content/22/suppl\\_5](http://annonc.oxfordjournals.org/content/22/suppl_5)

(2010) – ESMO GI 12<sup>th</sup> [http://annonc.oxfordjournals.org/content/21/suppl\\_6](http://annonc.oxfordjournals.org/content/21/suppl_6)

## **B2. ASCO (American Society of Clinical Oncology)**

This includes ASCO annual meeting 2010~2014, ASGO Gastrointestinal Oncology 2010~2014. The URL is shown at supplement table 1.

## **B3. UEGW (United European Gastroenterology Week)**

<https://www.ueg.eu/education/library/>

<https://www.ueg.eu/education/library/#stq=pancreatic%20cancer&stp=1>

Because SAGE (Society of American Gastroenterology) launched the UEG journal from 2012, we could access the full text abstracts from 2013, 2014.

([http://www.eurekalert.org/pub\\_releases/2012-08/sp-stl083012.php](http://www.eurekalert.org/pub_releases/2012-08/sp-stl083012.php))

(2014) UEGW 22<sup>nd</sup> [http://ueg.sagepub.com/content/2/1\\_suppl.toc](http://ueg.sagepub.com/content/2/1_suppl.toc)

Oral presentations [http://ueg.sagepub.com/content/2/1\\_suppl/A1.full.pdf+html](http://ueg.sagepub.com/content/2/1_suppl/A1.full.pdf+html)

Poster presentations [http://ueg.sagepub.com/content/2/1\\_suppl/A132.full.pdf+html](http://ueg.sagepub.com/content/2/1_suppl/A132.full.pdf+html)

(2013) UEGW 21<sup>st</sup> [http://ueg.sagepub.com/content/1/1\\_suppl.toc](http://ueg.sagepub.com/content/1/1_suppl.toc)

Oral presentations [http://ueg.sagepub.com/content/1/1\\_suppl/A1.full.pdf+html](http://ueg.sagepub.com/content/1/1_suppl/A1.full.pdf+html)

Poster presentations [http://ueg.sagepub.com/content/1/1\\_suppl/A135.full.pdf+html](http://ueg.sagepub.com/content/1/1_suppl/A135.full.pdf+html)

#### **B4. DDW (Digestive Disease Week)**

<http://www.ddw.org/past-events/abstracts>

<http://www.giejournal.org/issues>

<http://www.gastrojournal.org/issues>

(2014) DDW [http://www.giejournal.org/issue/S0016-5107\(14\)X0004-0](http://www.giejournal.org/issue/S0016-5107(14)X0004-0)

(2013) DDW [http://www.giejournal.org/issue/S0016-5107\(13\)X0005-7](http://www.giejournal.org/issue/S0016-5107(13)X0005-7)

(2012) DDW [http://www.gastrojournal.org/issue/S0016-5085\(12\)X6001-3](http://www.gastrojournal.org/issue/S0016-5085(12)X6001-3)

(2011) DDW [http://www.gastrojournal.org/issue/S0016-5085\(11\)X6001-8](http://www.gastrojournal.org/issue/S0016-5085(11)X6001-8)

(2010) DDW [http://www.gastrojournal.org/issue/S0016-5085\(10\)X6001-2](http://www.gastrojournal.org/issue/S0016-5085(10)X6001-2)

► **Global search strategy:**

① pancrea\* AND

(cancer OR adenocarcinoma OR tumor OR neoplasm) AND

resectable AND

( (neo-adjuvant OR neoadjuvant) OR ( (preop\* OR pre-op\*) AND (chemo\* OR therap\*)))

② ((pancrea\* cancer ) OR (pancrea\* adenocarcinom\*) OR (pancrea\* tumor) OR (pancrea\*  
neoplasm\*))

AND

resectable AND

( (neo-adjuvant OR neoadjuvant) OR ( (preop\* OR pre-op\*) AND (chemo\* OR therap\*) ) )

## Appendix 2. Data Extraction Form (DEF)

### • Study Characteristics

Study ID		Reviewer	JL / HK / KP / SA
Title			
Author/ Year/ Nation			
Journal			
Hospital / Sample size	single center ( ), multicenter ( ) sample size: total ( ) = case ( ) + control ( )		
Study design	group I. conventional randomized controlled trial ( ) group II. quasi-randomized controlled trials ( ) non-randomized controlled trials ( ) double-armed prospective cohort studies ( )		

### • Demographic Characteristics

Age (median, range)	
Sex	
Cancer stage	entire ( ) = RPC ( ) + BRPC ( ) + LAPC ( ) + MPC ( )
Neoadjuvant setting	only CTx ( ), CCRT ( ), only RTx ( )
Neoadjuvant regimen	1. as a CTx ( ) or radiosensitizer ( ) 2. as a CTx ( ) or radiosensitizer ( )
outcome ( 1 ) = primary ( 2 ) = secondary	overall survival ( ) disease free survival ( ) R0 resection rate ( ) rate of missing for OP ( ) completion rate of multimodality treatment ( ) treatment-related toxicity ( )

### • Check for Exclusion

1. other than English	( ) yes	( ) unclear	( ) no
2. other than clinical trial	( ) yes	( ) unclear	( ) no
3. only for pediatric population	( ) yes	( ) unclear	( ) no
4. other than original article	( ) yes	( ) unclear	( ) no
5. duplication again	( ) yes	( ) unclear	( ) no
6. pathologically other than adenocarcinoma	( ) yes	( ) unclear	( ) no
7. not including resectable PC	( ) yes	( ) unclear	( ) no
8. not including neoadjuvant CTx	( ) yes	( ) unclear	( ) no
9. single-armed study	( ) yes	( ) unclear	( ) no
10. vague study design	( ) yes	( ) unclear	( ) no

REVIEW DATE (YY/MM/DD) \_\_\_\_\_